Professor Jair Bar speaks to ecancer about the KEYNOTE-782 trial.

This trial aimed to determine the correlation between blood tumour mutational burden (bTMB) and the efficacy of first-line pembrolizumab plus chemotherapy in patients with non-small cell lung cancer (NSCLC).

The study's results showed that the adverse events observed were consistent with the known safety profile of first-line pembrolizumab plus chemotherapy in NSCLC.

However, the baseline bTMB did not show any evidence of being associated with efficacy.